Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm
Mandate

Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm

June 11, 2021 Capital Markets and Public M&A Corporate Tax M&A

Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market. The prospectus was published on 8 June 2021 and the trading on Nasdaq Stockholm commenced on 11 June 2021.

Sdiptech is a technology group that acquires and develops market-leading niche operations that contribute to creating more sustainable, efficient and safe societies. Sdiptech has approximately SEK 2,000 million in sales and is based in Stockholm.

Vinge’s team has primarily consisted of Dain Hård Nevonen, William Kåge, Anders Sundin Lundberg and Benjamin Vafaeian (Capital Markets and Public M&A), Jesper Lindvall and Eléonore Friberg (M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025